Avinza Extended-Release Capsules No Longer Being Manufactured
The Food and Drug Administration (FDA) has announced that all strengths of Avinza (morphine sulfate) extended release capsules have been discontinued. Avinza is a Schedule II long acting opioid medication indicated for the treatment of severe pain only. Avinza carried a black box warning indicating that misuse could lead to death due to the lack of non-abuse deterrent formulation. Pfizer has indicated that with the release of Embeda, morphine sulfate and naltrexone HCl in an abuse deterrent capsule, they have elected to remove the Avinza from the market.